WO2002055663A3 - Srebp pathway modulation through targeting hisrs - Google Patents

Srebp pathway modulation through targeting hisrs Download PDF

Info

Publication number
WO2002055663A3
WO2002055663A3 PCT/US2002/001045 US0201045W WO02055663A3 WO 2002055663 A3 WO2002055663 A3 WO 2002055663A3 US 0201045 W US0201045 W US 0201045W WO 02055663 A3 WO02055663 A3 WO 02055663A3
Authority
WO
WIPO (PCT)
Prior art keywords
hisrs
targeting
srebp pathway
pathway modulation
srebp
Prior art date
Application number
PCT/US2002/001045
Other languages
French (fr)
Other versions
WO2002055663A2 (en
Inventor
Cynthia Seidel-Dugan
Lisa C Kadyk
Phelipa A Mapa
Original Assignee
Exelixis Inc
Cynthia Seidel-Dugan
Lisa C Kadyk
Phelipa A Mapa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Cynthia Seidel-Dugan, Lisa C Kadyk, Phelipa A Mapa filed Critical Exelixis Inc
Priority to JP2002556714A priority Critical patent/JP2004524021A/en
Priority to EP02713405A priority patent/EP1356079A4/en
Priority to US10/466,161 priority patent/US20040101879A1/en
Priority to AU2002245257A priority patent/AU2002245257A1/en
Publication of WO2002055663A2 publication Critical patent/WO2002055663A2/en
Publication of WO2002055663A3 publication Critical patent/WO2002055663A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)

Abstract

Human HisRS genes are identified as modulators of the SREPB pathway and thus are therapeutic for disorders associated with the SREBP pathway. Methods for identifying modulators of HisRS, comprising screening for agents that modulate the activity of HisRS are provided.
PCT/US2002/001045 2001-01-12 2002-01-11 Srebp pathway modulation through targeting hisrs WO2002055663A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2002556714A JP2004524021A (en) 2001-01-12 2002-01-11 Regulation of the SREBP pathway by targeting HisRS
EP02713405A EP1356079A4 (en) 2001-01-12 2002-01-11 Srebp pathway modulation through targeting hisrs
US10/466,161 US20040101879A1 (en) 2002-01-11 2002-01-11 Srebp pathway modulation through targeting hisrs
AU2002245257A AU2002245257A1 (en) 2001-01-12 2002-01-11 Srebp pathway modulation through targeting hisrs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26156901P 2001-01-12 2001-01-12
US60/261,569 2001-01-12

Publications (2)

Publication Number Publication Date
WO2002055663A2 WO2002055663A2 (en) 2002-07-18
WO2002055663A3 true WO2002055663A3 (en) 2002-09-19

Family

ID=22993896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/001045 WO2002055663A2 (en) 2001-01-12 2002-01-11 Srebp pathway modulation through targeting hisrs

Country Status (4)

Country Link
EP (1) EP1356079A4 (en)
JP (1) JP2004524021A (en)
AU (1) AU2002245257A1 (en)
WO (1) WO2002055663A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835387B2 (en) 2012-02-16 2014-09-16 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US8969301B2 (en) 2010-07-12 2015-03-03 Atyr Pharma Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-tRNA synthetases
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
US9422539B2 (en) 2010-07-12 2016-08-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases
US9428743B2 (en) 2010-08-25 2016-08-30 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
US9540628B2 (en) 2009-12-11 2017-01-10 Atyr Pharma, Inc. Aminoacyl tRNA synthetases for modulating inflammation
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100092434A1 (en) 2008-06-11 2010-04-15 Atyr Pharma, Inc. Thrombopoietic activity of tyrosyl-trna synthetase polypeptides
WO2009158649A1 (en) 2008-06-26 2009-12-30 Atyr Pharma, Inc. Compositions and methods comprising glycyl-trna synthetases having non-canonical biological activities
WO2010099477A2 (en) 2009-02-27 2010-09-02 Atyr Pharma, Inc. Polypeptide structural motifs associated with cell signaling activity
WO2010107825A2 (en) 2009-03-16 2010-09-23 Pangu Biopharma Limited Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
JP5848236B2 (en) 2009-03-31 2016-01-27 エータイアー ファーマ， インコーポレイテッド Compositions and methods comprising aspartyl tRNA synthetase with non-standard biological activity
US8828395B2 (en) 2009-12-11 2014-09-09 Atyr Pharma, Inc. Antibodies that bind tyrosyl-tRNA synthetases
EP2593125B1 (en) 2010-07-12 2017-11-01 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
US9714419B2 (en) 2011-08-09 2017-07-25 Atyr Pharma, Inc. PEGylated tyrosyl-tRNA synthetase polypeptides
US9822353B2 (en) 2011-12-06 2017-11-21 Atyr Pharma, Inc. PEGylated aspartyl-tRNA synthetase polypeptides
WO2013086216A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Improved aspartyl-trna synthetases
JP6169608B2 (en) 2011-12-29 2017-07-26 エータイアー ファーマ， インコーポレイテッド Aspartyl tRNA synthetase-Fc conjugate
WO2015027171A1 (en) * 2013-08-23 2015-02-26 Quintiles Transnational Corporation Methods for predicting toxicity in response to treatment with a drug by assessing activation of the sterol regulatory binding protein (srebp) pathway
JP2020517638A (en) 2017-04-20 2020-06-18 エータイアー ファーマ， インコーポレイテッド Compositions and methods for treating lung inflammation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1196026A1 (en) * 1999-06-14 2002-04-17 Exelixis, Inc. Animal models and methods for analysis of lipid metabolism and screening of pharmaceutical and pesticidal agents that modulate lipid metabolism

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP1356079A4 *
XU ET AL.: "Sterol regulatory element binding protein-1 expression is suppressed by dietary polyunsaturated fatty acids", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 33, August 1999 (1999-08-01), pages 23577 - 23583, XP002951682 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540628B2 (en) 2009-12-11 2017-01-10 Atyr Pharma, Inc. Aminoacyl tRNA synthetases for modulating inflammation
US8969301B2 (en) 2010-07-12 2015-03-03 Atyr Pharma Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-tRNA synthetases
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
US9315794B2 (en) 2010-07-12 2016-04-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-tRNA synthetases
US9422539B2 (en) 2010-07-12 2016-08-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases
US9428743B2 (en) 2010-08-25 2016-08-30 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
US8835387B2 (en) 2012-02-16 2014-09-16 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US9273302B2 (en) 2012-02-16 2016-03-01 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates

Also Published As

Publication number Publication date
EP1356079A4 (en) 2005-10-19
AU2002245257A1 (en) 2002-07-24
WO2002055663A2 (en) 2002-07-18
JP2004524021A (en) 2004-08-12
EP1356079A2 (en) 2003-10-29

Similar Documents

Publication Publication Date Title
WO2002099049A3 (en) Tbc1d1s as modifiers of the p53 pathway and methods of use
WO2002098356A3 (en) Ppp2cs as modifiers of the p53 pathway and methods of use
WO2003073823A3 (en) PDPK1s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2002055663A3 (en) Srebp pathway modulation through targeting hisrs
WO2003014301A3 (en) Hprp4s as modifiers of the p53 pathway and methods of use
WO2002098891A3 (en) GADs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2003051905A3 (en) Taojiks as modifiers of the beta-catenin pathway and methods of use
WO2002099043A8 (en) P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2003035831A3 (en) Lrrcaps as modifiers of the p53 pathway and methods of use
WO2003033656A3 (en) MSREBPs AS MODIFIERS OF THE SREBP PATHWAY AND METHODS OF USE
WO2003054159A3 (en) Modulating insulin receptor signaling through targeting facl
WO2003052068A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2004065542A3 (en) MAT2As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2003052066A3 (en) Klcs as modifiers of the p53 pathway and methods of use
WO2003066811A3 (en) Msrebps as modifiers of the srebp pathway and methods of use
WO2003052070A3 (en) Vps41s as modifiers of cell death and methods of use
WO2004024881A3 (en) LDLRs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2003052069A3 (en) FLJ1115 AS MODIFIER OF THE Apaf-1 PATHWAY AND METHODS OF USE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002556714

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002713405

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002713405

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10466161

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002713405

Country of ref document: EP